ArticleAntibiotics (Basel, Switzerland)2021
Exploring the Antivirulence Activity of Pulverulentone A, a Phloroglucinol-Derivative from
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- LC-QTOF-MS metabolic profiling and anti-MRSA activity ofRSC advances · 2026Article
- Headspace GC-MS volatiles profiling in leaves of 4 Cymbopogon species and their vapor-phase antibacterial effects.Scientific reports · 2026Article
- Article
- Ketoprofen-loaded quatsomes as a smart repurposed antifungal therapy for vaginal infections: formulation, characterization, and microbiological evaluation.Frontiers in pharmacology · 2026Article
- Targeting virulence of resistant Escherichia coli by the FDA-approved drugs sitagliptin and nitazoxanide as an alternative antimicrobial approach.Folia microbiologica · 2025Article
- Design, Characterization, Antimicrobial Activity, andACS omega · 2025Article
- The Promising Effect of Ascorbic Acid and Paracetamol as Anti-Biofilm and Anti-Virulence Agents against ResistantCurrent issues in molecular biology · 2024Article
- Prodigiosin as an Antibiofilm Agent against the Bacterial Biofilm-Associated Infection ofPathogens (Basel, Switzerland) · 2024Article
- Investigation of the phytochemical composition, antioxidant, antibacterial, anti-osteoarthritis, and wound healing activities of selected vegetable waste.Scientific reports · 2023Article
- Antibacterial and anti-biofilm activities of Disaspidin BB againstFrontiers in microbiology · 2023Article
- In Vitro and In Vivo Antibiofilm Activity of Red Onion Scales: An Agro-Food Waste.Molecules (Basel, Switzerland) · 2023Article
- The Untargeted Phytochemical Profile of Three Meliaceae Species Related to In Vitro Cytotoxicity and Anti-Virulence Activity against MRSA Isolates.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
(1) Background: Bacterial resistance to antibiotics is a global life-threatening issue. Antivirulence therapy is a promising approach to combat bacterial infections as it disarms the bacteria from their virulence factors with reduced selective pressure and a lower chance of resistance. (2) Methods:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.